Viral Vector Manufacturing
The global gene therapy market size is evaluated at $710 million as of 2018 and forecasted to grow with a CAGR of 31.5% from 2019 - 2025.
As of the end of 2019 there were 1,000 gene therapies in active or actively recruiting clinical trials. That number is expected to increase.
Our gene therapy services help overcome several hurdles in viral vector manufacturing including the use of adherent host cell lines, virus stability, limitations in virus characterization, and the lack of appropriate sensors and models to enable closed-loop control and optimization of virus manufacturing processes.
Overcome Production Challenges
In recent years, numerous companies have entered clinical trials with viral vectors. However, several challenges continue to exist, including capacity issues related to plasmid and virus production, virus stability, toxicity of the virus to the host cell lines, and a limited ability to properly characterize the active virus product.
These challenges have impacted consistent supply and product quality. BioCentriq's gene therapy experts will work with you to address these challenges in our manufacturing suites.
Get In Touch
Tell us about your next project or greatest challenge and we'll contact you to discuss how we can help.